NRXP Company Profile and Key Details

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) closed at $2.38 USD, gaining $0.01 (0.63%) from the previous close of $2.37. The stock is currently mid-range between its 52-week high and low $1.40 and $6.01. With a market capitalization of about $41.23 million, NRx Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.92). Key stats such as the average daily volume over the past year has been around 476.53 thousand shares, in line with its 52-week average. Headquartered in Wilmington, DE, NRx Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan C. Javitt, the company employs approximately 2 people and listed since December 04, 2017. NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

The latest quarter delivered EPS of -$0.18. The next quarter is forecast at $0.01. Next year's EPS is expected at $49.45. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 31 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $47.00 to $18.00. The high target offers 1883.12% upside. The low target suggests 659.49% downside. The mean target is $32.16. This offers 1256.96% upside. NRx Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 63.64%. The prior quarter beat by 13.33%. Over the last six quarters, Apple has recorded several small beats. These include -99.91% in August 12, 2024.

NRx Pharmaceuticals, Inc. has 23.77 million shares outstanding. The public float is 13.61 million shares, elevated short interest at 3.03% of float. This equals 545.48 thousand shares. The short ratio is 2.06 days. Institutional investors hold 28.8% of the float. Insiders own 11.55%. Javitt Daniel C. holds 9.63 million shares, Hurvitz Chaim has 570.00 thousand shares and Polar Asset Management Partners Inc. has 488.04 thousand shares.

NRXP has shown mixed momentum, gaining 7.73% over the past week and -20.2% over the past quarter, though year-to-date performance is up 7.73%. Short-term trend indicators are bullishly aligned (SMA20 4.84%, SMA50 -8.8%, SMA200 -10.3%). The stock’s 14-day RSI is 51.02 (neutral), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -60.57% below its high and over 69.29% above its low. Average 10-day trading volume of 690.64 thousand shares is slightly above the 3-month average of 462.64 thousand, indicating heightened recent market interest.

NRx Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.49. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that NRx Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.8%, with price expected at $2.28 by January 02, 2026, within a range of $2.12 to $2.46 3-Month Outlook: Projected rise of 240.08%, reaching $8.06 by March 19, 2026, with a range of $7.91 to $8.35. 1-Year Outlook: Projected gain of 118.14%, with price at $5.17 by December 18, 2026, within a range of $2.02 to $6.18.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) shares are flat 7.73% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NRx Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -1.38. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.11, suggesting 1170.46% upside. Our AI forecast model points to short-term weakness (-3.8% over two weeks), a medium-term rise (240.08% over three months), and a longer-term gain (118.14% over one year), with expected trading ranges indicating moderate volatility.

NRx Pharmaceuticals, Inc. trades at a P/E ratio of -1.38, slightly below the S&P 500 average, with a price-to-sales ratio of 166.53 and a price-to-book ratio of -2.05 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.28, also below market averages.